证券日报网讯 1月20日，华特达因在互动平台回答投资者提问时表示，公司严格按照中国证监会和深交 所的相关要求组织年度报告编制和披露工作，2025年度预计经营业绩不属于应当披露业绩预告的范围， 年度报告预约披露时间为2026年4月24日。 （文章来源：证券日报） ...

证券日报网讯 1月20日，华特达因在互动平台回答投资者提问时表示，公司聚焦主业，以儿童临床需求 和营养健康需要为导向，着力构建两大类系统化产品矩阵，一是在"伊可新"基础上进行品类延伸，形成 包含营养、呼吸、消化、精神等领域的儿童用药产品矩阵，二是以"伊可新"品牌延伸，形成涵盖基础营 养、眼脑发育、肠道健康、免疫健康、皮肤护理五大领域的儿童大健康产品矩阵，未来公司将继续进一 步丰富儿童药品和健康产品矩阵，通过多元化产品满足不同年龄段青少年多元化的营养健康需求，不断 巩固和发展公司核心竞争能力和经营业绩。 （编辑 楚丽君） ...

人民财讯1月20日电，华特达因（000915）1月20日在互动平台表示，公司目前与雀巢公司没有业务往 来。 ...

证券日报网讯1月13日，华特达因（000915）在互动平台回答投资者提问时表示，公司褪黑素颗粒产品 曼乐静前期为意向预约，本周将在阿里和京东线上正式销售，也将陆续进入国内各地医院销售。 ...

证券日报网讯1月13日，华特达因（000915）在互动平台回答投资者提问时表示，公司褪黑素颗粒产品 曼乐静本周即可在阿里和京东线上根据医生处方购买，后续将陆续进入国内各地医院销售。 ...

Core Viewpoint - The announcement highlights that Shandong Huate Dain Health Co., Ltd.'s subsidiary, Dain Pharmaceutical, has received a drug registration certificate for a medication aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6-17, which is expected to enhance the company's product pipeline and competitive position in the pediatric health sector [1][2]. Group 1: Drug Registration Certificate Details - Dain Pharmaceutical has obtained the drug registration certificate for Clonidine Hydrochloride Extended-Release Tablets, with the certificate number 2025S03966 [1]. - The medication is intended for the treatment of ADHD in children and adolescents aged 6-17, either alone or as an adjunct to central nervous system stimulants [1]. Group 2: Impact on the Company - The acquisition of the drug registration certificate is anticipated to enrich the company's product line in the ADHD treatment area, supporting the realization of its strategic development and enhancing its competitiveness [2]. - The introduction of this medication is expected to positively impact the company's commitment to children's health and its performance [2].

Core Viewpoint - The company announced that its subsidiary, Dain Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Clonidine Hydrochloride Extended-Release Tablets, specifically for the treatment of ADHD in children aged 6-17 years [2] Group 1 - The approved product is Clonidine Hydrochloride Extended-Release Tablets with a specification of 0.1mg [2] - The approval number for the product is Guoyao Zhunzi H20256411, and it is valid until December 29, 2030 [2]

Core Viewpoint - The company Huate Dain has received a drug registration certificate from the National Medical Products Administration for its product, Clonidine Hydrochloride Sustained-Release Tablets, aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years [1] Group 1 - The drug is intended for use either alone or as an adjunct to central nervous system stimulants in the treatment of ADHD [1]

Core Viewpoint - Huatai Dain (000915.SZ) announced that its subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd. (referred to as Dain Pharmaceutical), has received a Drug Registration Certificate from the National Medical Products Administration for its product, Clonidine Hydrochloride Sustained-Release Tablets, which is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6-17 years [1] Group 1 - The product is specifically used as a standalone or adjunctive treatment with central nervous system stimulants for ADHD [1]

Core Viewpoint - The company announced that its subsidiary, Shandong Dain Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for a new medication, Clonidine Hydrochloride Sustained-Release Tablets, aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6-17 years [1] Group 1 - The drug is indicated for use either alone or as an adjunct to central nervous system stimulants in the treatment of ADHD [1]